. Author manuscript; available in PMC: 2011 Dec 1.

Published in final edited form as: Pain. 2010 Sep 20;151(3):732–736. doi: 10.1016/j.pain.2010.08.045

Table 1.

Cohort Characteristics

Age, mean (SD)	43.9 (9.1)
Gender	82 % male 18% female
Ethnicity	35% African-American 14% Hispanic 49% white 3% other
Education, mean (SD)	12.8 (2.5)
Past or current substance abuse^*	79%
Self-report of IVDU as HIV risk-factor	17%
Positive urine toxicology	18%
Current major depressive disorder^*	12%
Beck Depression Inventory, median [IQR]	9 [3,16]
Current psychiatric medication use^**	53%
Current CD4+ cells (cells/mm³), median [IQR]	500 (321-711)
Nadir CD4+ cells (cells/mm³), median [IQR]	200 (51-333)
Plasma HIV viral load (log₁₀(copies/ml), median [IQR]	1.76 (1.69-3.82)

Diagnosed using the Composite International Diagnostic Interview (CIDI)

^**

Psychiatric medications included were antipsychotics, antidepressants (other than duloxetine and tricyclic antidepressants), mood stabilizers (other than the anticonvulsants e.g. gabapentin, lamotrigine, valproate, pregabalin) sedatives/hypnotics, or stimulants. These criteria were adopted in an effort to exclude medications that are commonly used for both psychiatric and non-psychiatric purposes.